Not provided
Not provided
Not provided
Not provided
Study was terminated due to feasibility concerns and budget constraints.
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Autoimmunity Centers of Excellence | OTHER |
| Northwell Health | OTHER |
Not provided
Not provided
Not provided
Not provided
The study is a multicenter, double-blind, sham-controlled trial to evaluate the safety and effectiveness of tcVNS on pain and inflammation associated with JIA. tcVNS is administered with a device that gives off mild electrical impulses through the skin to stimulate the vagus nerve. Part of the vagus nerve and its branches are located in the head and neck. For this study, the impulses will be administered using a small electrode at the cymba concha for participants receiving treatment with active tcVNS and at the neck for participants receiving sham stimulation. The electrode helps to conduct the stimulation through the skin. This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.
The primary objective of this study is to determine the effect of tcVNS on JIA ACR 50 in participants with active JIA. The components of the active and sham tcVNS devices, utilizing the Roscoe Medical TENS 7000, have been FDA 510(k)-cleared and have been determined by the IRB to be a nonsignificant risk device.
AJA01 is a multicenter, double-blind, sham-controlled, 16-week trial to evaluate the safety and effectiveness of tcVNS for the treatment of JIA.
A total of 100 participants will be randomized 1:1 to treatment with active tcVNS at the cymba concha or sham stimulation at the neck for 5 minutes once a day for 8 weeks. During this time, participants/parents, and participant assessors will be blinded to treatment assignment; treatments on clinic visit days will be conducted in the clinic under the supervision of a trained, unblinded staff member, and participants will only discuss the stimulation procedure with this staff member. An unblinded site investigator will follow up on any safety events. The double-blind, sham-controlled 8-week period will be followed by an 8-week open-label period in which all participants will receive treatment with active tcVNS at the cymba concha once a day for 5 minutes. Participants and their parents will be told it is likely they will feel the stimulation, but it should not be painful.
There are 10 visits for the study, 8 clinic visits and 2 tele-visits. Participants will have physical exams with joint assessments, lab tests, and questionnaire completion by the physicians and participants at each clinic visit. Participants will be trained by the unblinded coordinator to perform stimulation during the clinic visit following the randomization. Participants will perform the stimulation at home for 5 minutes daily. Participants will complete a diary to document the daily stimulation.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Blinded phase | Experimental | Participants will receive 5 minutes of active tcVNS or sham tcVNS daily for 8 weeks. |
|
| Open-Label phase | Experimental | Participants will receive 5 minutes of stimulation via the active tcVNS device for 8 weeks after a double-blind, sham-controlled 8- week period. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Active tcVNS | Device | Participants being treated with an active tcVNS device will attach the stimulator, lead, and clip electrode to assemble the complete device and coat the electrode surfaces with electrode gel. The electrode will be placed on the cymba concha of a left ear that is free of earrings or other objects, cleaned internally and externally, and coated with a thin layer of electrode gel. The participant will gradually advance the stimulator knob clockwise until they feel the electrical stimulation at a level that is easily tolerated for 5 minutes and is not painful. The participant will apply the stimulation for 5 minutes, then the participant will turn off the stimulator, remove the electrode from the ear, and clean the ear and electrodes with gauze. |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Responders at Week 8 Compared to Baseline | The JIA ACR 50 is a validated composite response consisting of 6 core criteria: number of joints with active arthritis; number of joints with limited motion; physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); a validated measure of physical function, Childhood Health Assessment Questionnaire (CHAQ); and a laboratory measure of inflammation, c-Reactive Protein (CRP). The JIA ACR 50 is achieved if 3 of any 6 core set variables improved by at least 50% from Baseline, and no more than 1 variable worsens by >30%. A negative change from Baseline in any of the core set variables signifies improvement. Participants missing any of the JIA ACR core criteria at Week 8 are imputed as JIA ACR 50 non-responders at Week 8. | Week 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Responders at Weeks 4, 12, and 16 Compared to Baseline | The JIA ACR 50 is a validated composite response consisting of 6 core criteria: number of joints with active arthritis; number of joints with limited motion; physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); a validated measure of physical function, Childhood Health Assessment Questionnaire (CHAQ); and a laboratory measure of inflammation, c-Reactive Protein (CRP). The JIA ACR 50 is achieved if 3 of any 6 core set variables improved by at least 50% from Baseline, and no more than 1 variable worsens by >30%. A negative change from Baseline in any of the core set variables signifies improvement. Participants missing any of the JIA ACR core criteria at any visit are imputed as JIA ACR 50 non-responders at that visit. |
Not provided
Inclusion Criteria:
Participant is 5 through 18 years of age (inclusive) at screening.
Regarding informed consent and compliance:
The participant has a Juvenile Idiopathic Arthritis (JIA) diagnosis meeting International League of Associations for Rheumatology (ILAR) classification criteria with one of the following subtypes:
The participant has >=3 joints with active arthritis at screening
If the participant is receiving therapy for JIA at screening, that therapy is stable for the time period outlined below and is expected to remain stable for the duration of the study:
a. stable dose for at least 1 week prior to screening:
i. Oral steroids, <= 0.2 mg/kg/day with a maximum 10 mg/day dose
b. stable dose for at least 2 weeks prior to screening:
i. NSAIDs
c. stable dose for at least 8 weeks prior to screening:
i. adalimumab
ii. anakinra
iii. canakinumab
iv. certolizumab pegol
v. etanercept
vi. golimumab
vii. infliximab
viii. leflunomide
ix. methotrexate
x. tocilizumab
d. stable dose for at least 12 weeks prior to screening:
i. abatacept
If a female of child-bearing potential, the participant has a negative urine pregnancy test at screening
If of reproductive potential, must agree to abstinence or effective methods of birth control for the duration of the study
Exclusion Criteria:
Other than NSAIDs or intra-articular injections, participant has been treated for JIA with lack of efficacy with:
Participant has received high-dose steroids (>=0.2 mg/kg/day) within the 28 days prior to screening.
Participant has had active systemic disease (fever, systemic rash) within the 3 months prior to screening including any of the following lab manifestations at screening:
Participant has had an active acute systemic infection within 2 weeks of screening. involving fever (100.4⁰F or higher) for more than 24 hours, requirement for systemic antibiotics or antivirals, GI symptoms lasting 48 hours or more, or the need to hold second line medications for JIA (methotrexate or biologic).
Participant has a history of arrhythmia.
Participant has been diagnosed with postural orthostatic tachycardia syndrome (POTS).
Participant has received an intra-articular cortisone injection within the 28 days prior to screening.
Participant has received treatment with an investigational drug or device during the 28 days prior to screening or within five half-lives of the investigational drug prior to screening/baseline, whichever is the greater length of time.
Participant has received chronic treatment with an anti-cholinergic medication, including over the counter medications.
Participant has received treatment with rituximab:
Participant has a comorbid disease that has required treatment with corticosteroids within the past year.
Participant has an implantable electronic device such as a pacemaker, defibrillator, hearing aid, cochlear implant, insulin pump or deep brain stimulator.
Participant has used cutaneous vagus nerve stimulation within 12 weeks prior to screening.
Participant has received a live attenuated viral vaccine within 28 days prior to screening or is expected to receive one during the study.
Participant has any condition which, in the opinion of the investigator, would jeopardize the participant's safety following exposure to a study intervention.
Participant has any past or current medical problems or findings from a physical examination or laboratory testing that are not listed above but which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or may impact the quality or interpretation of the data obtained from the study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Beth Gottlieb, MD | Feinstein Institutes for Medical Research, Cohen Children's Medical Center: Pediatric Rheumatology | Study Chair |
| Cynthia Aranow, MD | Northwell Health | Study Chair |
| Timir Datta-Chaudhuri, PhD | Northwell Health | Study Chair |
| Betty Diamond, MD | Northwell Health | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California San Francisco School of Medicine: Department of Pediatrics, Division of Pediatric Rheumatology | San Francisco | California | 94158 | United States |
Not provided
| Label | URL |
|---|---|
| Autoimmunity Centers of Excellence (ACE) | View source |
| National Institute of Allergy and Infectious Diseases (NIAID) | View source |
| Division of Allergy, Immunology, and Transplantation (DAIT) |
Not provided
The plan is to share data upon completion of the study in the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from the Division of Allergy Immunology and Transplantation-funded grants and contracts.
Not provided
On average, within 24 months after database lock for the trial.
Open access.
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Active tcVNS | Participants in the Active tcVNS arm stimulated themselves for 5 minutes daily with the investigational device at the cymba concha through Week 16. |
| FG001 | Sham Stimulation | Participants in the Sham Stimulation arm stimulated themselves for 5 minutes daily with sham stimulation at the neck through the day prior to the Week 8 visit and then stimulated for 5 minutes daily with active tcVNS at the cymba concha using the investigational device from Week 8 through Week 16. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
The modified Intent-to-Treat (mITT) population included all randomized participants who received any active tcVNS stimulation or sham stimulation.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Active tcVNS | Participants in the Active tcVNS arm stimulated themselves for 5 minutes daily with the investigation device at the cymba concha through Week 16. |
| BG001 | Sham Stimulation |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Proportion of Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Responders at Week 8 Compared to Baseline | The JIA ACR 50 is a validated composite response consisting of 6 core criteria: number of joints with active arthritis; number of joints with limited motion; physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); a validated measure of physical function, Childhood Health Assessment Questionnaire (CHAQ); and a laboratory measure of inflammation, c-Reactive Protein (CRP). The JIA ACR 50 is achieved if 3 of any 6 core set variables improved by at least 50% from Baseline, and no more than 1 variable worsens by >30%. A negative change from Baseline in any of the core set variables signifies improvement. Participants missing any of the JIA ACR core criteria at Week 8 are imputed as JIA ACR 50 non-responders at Week 8. | The modified Intent-to-Treat (mITT) population included all randomized participants who received any active tcVNS stimulation or sham stimulation. | Posted | Number | 95% Confidence Interval | Proportion of Participants | Week 8 |
Treatment-emergent adverse events were recorded in EDC from after initiation of stimulation at Day 0 to Week 16.
The following AEs were recorded in EDC:
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Blinded Phase: Active tcVNS | Participants stimulated themselves for 5 minutes daily with active tcVNS at the cymba concha using the investigational device through the day prior to the Week 8 visit. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Palpitations | Cardiac disorders | 26.0 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Director, Clinical Research Operations Program | DAIT/NIAID | 301-594-7669 | DAITClinicalTrialsGov@niaid.nih.gov |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Apr 9, 2024 | Oct 15, 2025 | Prot_SAP_001.pdf |
| ICF | No | No | Yes | Informed Consent Form | May 23, 2023 | Aug 6, 2025 | ICF_000.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001171 | Arthritis, Juvenile |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Sham tcVNS | Device | Participants being treated with a sham tcVNS device will place adhesive electrodes on the left side of the neck, which has had neck jewelry removed and has been cleaned at the site of treatment. The participant will then connect the lead to the electrodes and the stimulator to assemble the complete sham tcVNS device. The participant will gradually advance the stimulator knob clockwise until they feel the electrical stimulation at a level that is easily tolerated for 5 minutes and is not painful. Participants in this group will be instructed to not turn the knob above "3" on the dial as this is the maximum acceptable treatment level at the neck. The participant will apply the stimulation for 5 minutes, then the participant will turn off the stimulator, remove the electrode from the neck, and dispose of the electrodes. |
|
|
| Active tcVNS | Device | Participants being treated with an active tcVNS device will attach the stimulator, lead, and clip electrode to assemble the complete device and coat the electrode surfaces with electrode gel. The electrode will be placed on the cymba concha of a left ear that is free of earrings or other objects, cleaned internally and externally, and coated with a thin layer of electrode gel. The participant will gradually advance the stimulator knob clockwise until they feel the electrical stimulation at a level that is easily tolerated for 5 minutes and is not painful. The participant will apply the stimulation for 5 minutes, then the participant will turn off the stimulator, remove the electrode from the ear, and clean the ear and electrodes with gauze. |
|
|
| Weeks 4, 12, 16 |
| Proportion of Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Responders at Weeks 4, 8, 12, and 16 Compared to Baseline | The JIA ACR 30 is a validated composite response consisting of 6 core criteria: number of joints with active arthritis; number of joints with limited motion; physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); a validated measure of physical function, Childhood Health Assessment Questionnaire (CHAQ); and a laboratory measure of inflammation, c-Reactive Protein (CRP). The JIA ACR 30 is achieved if 3 of any 6 core set variables improved by at least 30% from Baseline, and no more than 1 variable worsens by >30%. A negative change from Baseline in any of the core set variables signifies improvement. Participants missing any of the JIA ACR core criteria at any visit are imputed as JIA ACR 30 non-responders at that visit. | Weeks 4, 8, 12, 16 |
| Proportion of Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Responders at Week 4, 8, 12, and 16 Compared to Baseline | The JIA ACR 70 is a validated composite response consisting of 6 core criteria: number of joints with active arthritis; number of joints with limited motion; physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); a validated measure of physical function, Childhood Health Assessment Questionnaire (CHAQ); and a laboratory measure of inflammation, c-Reactive Protein (CRP). The JIA ACR 70 is achieved if 3 of any 6 core set variables improved by at least 70% from Baseline, and no more than 1 variable worsens by >30%. A negative change from Baseline in any of the core set variables signifies improvement. Participants missing any of the JIA ACR core criteria at any visit are imputed as JIA ACR 70 non-responders at that visit. | Weeks 4, 8, 12, 16 |
| Change From Baseline in Juvenile Arthritis Disease Activity Score in 27 Joints (JADAS-27) at Weeks 4, 8, 12, and 16 | The JADAS-27 is a measurement of disease activity and is determined by adding the scores of its 4 components: physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); number of joints with active arthritis; and a laboratory measure of inflammation, c-Reactive Protein (CRP), normalized to a value between 0 and 10. The JADAS-27 includes the following joints: cervical spine, elbows, wrists, metacarpophalangeal joints (from first to third), proximal inter-phalangeal joints, hips, knees, and ankles. This provides a score in the range of 0-57 with higher scores indicating worse disease activity. A negative change from Baseline signifies improvement. | Baseline; Weeks 4, 8, 12, 16 |
| Proportion of Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Responders at Weeks 12 and 16 Compared to Week 8 | The JIA ACR 50 is a validated composite response consisting of 6 core criteria: number of joints with active arthritis; number of joints with limited motion; physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); a validated measure of physical function, Childhood Health Assessment Questionnaire (CHAQ); and a laboratory measure of inflammation, c-Reactive Protein (CRP). The JIA ACR 50 is achieved if 3 of any 6 core set variables improved by at least 50% from Week 8, and no more than 1 variable worsens by >30%. A negative change from Week 8 in any of the core set variables signifies improvement. Participants missing any of the JIA ACR core criteria at any visit are imputed as JIA ACR 50 non-responders at that visit. | Week 12 and 16 |
| Proportion of Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Responders at Weeks 12 and 16 Compared to Week 8 | The JIA ACR 30 is a validated composite response consisting of 6 core criteria: number of joints with active arthritis; number of joints with limited motion; physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); a validated measure of physical function, Childhood Health Assessment Questionnaire (CHAQ); and a laboratory measure of inflammation, c-Reactive Protein (CRP). The JIA ACR 30 is achieved if 3 of any 6 core set variables improved by at least 30% from Week 8, and no more than 1 variable worsens by >30%. A negative change from Week 8 in any of the core set variables signifies improvement. Participants missing any of the JIA ACR core criteria at any visit are imputed as JIA ACR 30 non-responders at that visit. | At Weeks 12 and 16 |
| Proportion of Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Responders at Week 12 and 16 Compared to Week 8 | The JIA ACR 70 is a validated composite response consisting of 6 core criteria: number of joints with active arthritis; number of joints with limited motion; physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); a validated measure of physical function, Childhood Health Assessment Questionnaire (CHAQ); and a laboratory measure of inflammation, c-Reactive Protein (CRP). The JIA ACR 70 is achieved if 3 of any 6 core set variables improved by at least 70% from Week 8, and no more than 1 variable worsens by >30%. A negative change from Week 8 in any of the core set variables signifies improvement. Participants missing any of the JIA ACR core criteria at any visit are imputed as JIA ACR 70 non-responders at that visit. | Weeks 12 and 16 |
| Change From Week 8 in Juvenile Arthritis Disease Activity Score in 27 Joints (JADAS-27) | The JADAS-27 is a measurement of disease activity and is determined by adding the scores of its 4 components: physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); number of joints with active arthritis; and a laboratory measure of inflammation, c-Reactive Protein (CRP) normalized to a value between 0-10. The JADAS-27 includes the following joints: cervical spine, elbows, wrists, metacarpophalangeal joints (from first to third), proximal inter-phalangeal joints, hips, knees, and ankles. This provides a score in the range of 0-57 with higher scores indicating worse disease activity. A negative change from Week 8 signifies improvement. | Weeks 12 and 16 |
| Longitudinal Trends From Baseline to Week 16 in Juvenile Arthritis Disease Activity Score in 27 Joints (JADAS-27) | The JADAS-27 is a measurement of disease activity and is determined by adding the scores of its 4 components: physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); number of joints with active arthritis; and a laboratory measure of inflammation, c-Reactive Protein (CRP) normalized to a value between 0-10. The JADAS-27 includes the following joints: cervical spine, elbows, wrists, metacarpophalangeal joints (from first to third), proximal inter-phalangeal joints, hips, knees, and ankles. This provides a score in the range of 0-57 with higher scores indicating worse disease activity. | Baseline; Weeks 4, 8, 12, 16 |
| Number of Participants With a Treatment-emergent Adverse Event From Day 0 to Week 8. | A participant who experienced any of the following untoward or unfavorable medical occurrence(s) associated with the investigational device or any study mandated procedures following the first stimulation on Day 0 and prior to the Week 8 visit:
| Day 0 to Week 8 |
| Number of Participants With a Treatment-emergent Adverse Event From Week 8 to Week 16 | A participant who experienced any of the following untoward or unfavorable medical occurrence(s) associated with the investigational device or any study mandated procedures between Week 8 and Week 16:
| Week 8 to Week 16 |
| Number of Participants With a Treatment-emergent Serious Adverse Event From Day 0 to Week 8 | A participant who experienced any serious untoward or unfavorable medical occurrence(s) associated with the investigational device or any study mandated procedures following the first stimulation on Day 0 and prior to the Week 8 visit. | Day 0 to Week 8 |
| Number of Participants With a Treatment-emergent Serious Adverse Event From Week 8 to Week 16 | A participant who experienced any serious untoward or unfavorable medical occurrence(s) associated with the investigational device or any study mandated procedures between Week 8 and Week 16. | Week 8 to Week 16 |
| Nemours Children's Health: Department of Pediatric Rheumatology | Orlando | Florida | 32827 | United States |
| Indiana University Medical Center: Riley Hospital for Children Department of Pediatric Rheumatology | Indianapolis | Indiana | 46202 | United States |
| Feinstein Institutes for Medical Research, Cohen Children's Medical Center: Pediatric Rheumatology | Lake Success | New York | 11040 | United States |
| Stephen D. Hassenfield Children's Center at NYU Langone Health | New York | New York | 10016 | United States |
| Division of Pediatric Rheumatology at the University of Utah School of Medicine and Primary Children's Hospital | Salt Lake City | Utah | 84132 | United States |
| Seattle Children's Hospital: Rheumatology Clinic | Seattle | Washington | 98105 | United States |
| Withdrew prior to first device stimulation |
|
Participants in the Sham Stimulation arm stimulated themselves for 5 minutes daily with sham stimulation at the neck through the day prior to the Week 8 visit and then stimulated for 5 minutes daily with active tcVNS at the cymba concha using the investigational device from Week 8 through Week 16.
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| JIA Subtype | JIA subtype at Baseline | Count of Participants | Participants |
|
| Number of Joints with Active Arthritis | Number of joints with active arthritis at Baseline. Active arthritis is non-boney swelling (joint effusion) or limitation of motion accompanied by warmth, pain on motion or tenderness to palpation. | Mean | Standard Deviation | Joints |
|
| Number of Joints with Limited Motion | Number of joints with limitation of motion at Baseline. | Mean | Standard Deviation | Joints |
|
| ID |
|---|
| Title |
|---|
| Description |
|---|
| OG000 | Active tcVNS | Participants in the Active tcVNS arm stimulated themselves for 5 minutes daily with the investigation device at the cymba concha through Week 16. |
| OG001 | Sham Stimulation | Participants in the Sham Stimulation arm stimulated themselves for 5 minutes daily with sham stimulation at the neck through the day prior to the Week 8 visit and then stimulated for 5 minutes daily with active tcVNS at the cymba concha using the investigational device from Week 8 through Week 16. |
|
|
|
| Secondary | Proportion of Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Responders at Weeks 4, 12, and 16 Compared to Baseline | The JIA ACR 50 is a validated composite response consisting of 6 core criteria: number of joints with active arthritis; number of joints with limited motion; physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); a validated measure of physical function, Childhood Health Assessment Questionnaire (CHAQ); and a laboratory measure of inflammation, c-Reactive Protein (CRP). The JIA ACR 50 is achieved if 3 of any 6 core set variables improved by at least 50% from Baseline, and no more than 1 variable worsens by >30%. A negative change from Baseline in any of the core set variables signifies improvement. Participants missing any of the JIA ACR core criteria at any visit are imputed as JIA ACR 50 non-responders at that visit. | The modified Intent-to-Treat (mITT) population included all randomized participants who received any active tcVNS stimulation or sham stimulation. | Posted | Number | 95% Confidence Interval | Proportion of participants | Weeks 4, 12, 16 |
|
|
|
|
| Secondary | Proportion of Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Responders at Weeks 4, 8, 12, and 16 Compared to Baseline | The JIA ACR 30 is a validated composite response consisting of 6 core criteria: number of joints with active arthritis; number of joints with limited motion; physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); a validated measure of physical function, Childhood Health Assessment Questionnaire (CHAQ); and a laboratory measure of inflammation, c-Reactive Protein (CRP). The JIA ACR 30 is achieved if 3 of any 6 core set variables improved by at least 30% from Baseline, and no more than 1 variable worsens by >30%. A negative change from Baseline in any of the core set variables signifies improvement. Participants missing any of the JIA ACR core criteria at any visit are imputed as JIA ACR 30 non-responders at that visit. | The modified Intent-to-Treat (mITT) population included all randomized participants who received any active tcVNS stimulation or sham stimulation. | Posted | Number | 95% Confidence Interval | Proportion of participants | Weeks 4, 8, 12, 16 |
|
|
|
|
| Secondary | Proportion of Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Responders at Week 4, 8, 12, and 16 Compared to Baseline | The JIA ACR 70 is a validated composite response consisting of 6 core criteria: number of joints with active arthritis; number of joints with limited motion; physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); a validated measure of physical function, Childhood Health Assessment Questionnaire (CHAQ); and a laboratory measure of inflammation, c-Reactive Protein (CRP). The JIA ACR 70 is achieved if 3 of any 6 core set variables improved by at least 70% from Baseline, and no more than 1 variable worsens by >30%. A negative change from Baseline in any of the core set variables signifies improvement. Participants missing any of the JIA ACR core criteria at any visit are imputed as JIA ACR 70 non-responders at that visit. | The modified Intent-to-Treat (mITT) population included all randomized participants who received any active tcVNS stimulation or sham stimulation. | Posted | Number | 95% Confidence Interval | Proportion of participants | Weeks 4, 8, 12, 16 |
|
|
|
|
| Secondary | Change From Baseline in Juvenile Arthritis Disease Activity Score in 27 Joints (JADAS-27) at Weeks 4, 8, 12, and 16 | The JADAS-27 is a measurement of disease activity and is determined by adding the scores of its 4 components: physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); number of joints with active arthritis; and a laboratory measure of inflammation, c-Reactive Protein (CRP), normalized to a value between 0 and 10. The JADAS-27 includes the following joints: cervical spine, elbows, wrists, metacarpophalangeal joints (from first to third), proximal inter-phalangeal joints, hips, knees, and ankles. This provides a score in the range of 0-57 with higher scores indicating worse disease activity. A negative change from Baseline signifies improvement. | The modified Intent-to-Treat (mITT) population included all randomized participants who received any active tcVNS stimulation or sham stimulation. | Posted | Least Squares Mean | 95% Confidence Interval | Score on a scale | Baseline; Weeks 4, 8, 12, 16 |
|
|
|
|
| Secondary | Proportion of Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Responders at Weeks 12 and 16 Compared to Week 8 | The JIA ACR 50 is a validated composite response consisting of 6 core criteria: number of joints with active arthritis; number of joints with limited motion; physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); a validated measure of physical function, Childhood Health Assessment Questionnaire (CHAQ); and a laboratory measure of inflammation, c-Reactive Protein (CRP). The JIA ACR 50 is achieved if 3 of any 6 core set variables improved by at least 50% from Week 8, and no more than 1 variable worsens by >30%. A negative change from Week 8 in any of the core set variables signifies improvement. Participants missing any of the JIA ACR core criteria at any visit are imputed as JIA ACR 50 non-responders at that visit. | The modified Intent-to-Treat (mITT) population included all randomized participants who received any active tcVNS stimulation or sham stimulation. | Posted | Number | 95% Confidence Interval | Proportion of Participants | Week 12 and 16 |
|
|
|
|
| Secondary | Proportion of Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Responders at Weeks 12 and 16 Compared to Week 8 | The JIA ACR 30 is a validated composite response consisting of 6 core criteria: number of joints with active arthritis; number of joints with limited motion; physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); a validated measure of physical function, Childhood Health Assessment Questionnaire (CHAQ); and a laboratory measure of inflammation, c-Reactive Protein (CRP). The JIA ACR 30 is achieved if 3 of any 6 core set variables improved by at least 30% from Week 8, and no more than 1 variable worsens by >30%. A negative change from Week 8 in any of the core set variables signifies improvement. Participants missing any of the JIA ACR core criteria at any visit are imputed as JIA ACR 30 non-responders at that visit. | The modified Intent-to-Treat (mITT) population included all randomized participants who received any active tcVNS stimulation or sham stimulation. | Posted | Number | 95% Confidence Interval | Proportion of Participants | At Weeks 12 and 16 |
|
|
|
|
| Secondary | Proportion of Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Responders at Week 12 and 16 Compared to Week 8 | The JIA ACR 70 is a validated composite response consisting of 6 core criteria: number of joints with active arthritis; number of joints with limited motion; physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); a validated measure of physical function, Childhood Health Assessment Questionnaire (CHAQ); and a laboratory measure of inflammation, c-Reactive Protein (CRP). The JIA ACR 70 is achieved if 3 of any 6 core set variables improved by at least 70% from Week 8, and no more than 1 variable worsens by >30%. A negative change from Week 8 in any of the core set variables signifies improvement. Participants missing any of the JIA ACR core criteria at any visit are imputed as JIA ACR 70 non-responders at that visit. | The modified Intent-to-Treat (mITT) population included all randomized participants who received any active tcVNS stimulation or sham stimulation. | Posted | Number | 95% Confidence Interval | Proportion of Participants | Weeks 12 and 16 |
|
|
|
|
| Secondary | Change From Week 8 in Juvenile Arthritis Disease Activity Score in 27 Joints (JADAS-27) | The JADAS-27 is a measurement of disease activity and is determined by adding the scores of its 4 components: physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); number of joints with active arthritis; and a laboratory measure of inflammation, c-Reactive Protein (CRP) normalized to a value between 0-10. The JADAS-27 includes the following joints: cervical spine, elbows, wrists, metacarpophalangeal joints (from first to third), proximal inter-phalangeal joints, hips, knees, and ankles. This provides a score in the range of 0-57 with higher scores indicating worse disease activity. A negative change from Week 8 signifies improvement. | The modified Intent-to-Treat (mITT) population included all randomized participants who received any active tcVNS stimulation or sham stimulation. | Posted | Least Squares Mean | 95% Confidence Interval | Score on a scale | Weeks 12 and 16 |
|
|
|
|
| Secondary | Longitudinal Trends From Baseline to Week 16 in Juvenile Arthritis Disease Activity Score in 27 Joints (JADAS-27) | The JADAS-27 is a measurement of disease activity and is determined by adding the scores of its 4 components: physician's assessment of disease activity (measured on a 10 cm visual analogue scale (VAS)); parent/patient assessment of overall well-being (measured on a 10 cm VAS); number of joints with active arthritis; and a laboratory measure of inflammation, c-Reactive Protein (CRP) normalized to a value between 0-10. The JADAS-27 includes the following joints: cervical spine, elbows, wrists, metacarpophalangeal joints (from first to third), proximal inter-phalangeal joints, hips, knees, and ankles. This provides a score in the range of 0-57 with higher scores indicating worse disease activity. | The modified Intent-to-Treat (mITT) population included all randomized participants who received any active tcVNS stimulation or sham stimulation. | Posted | Mean | Standard Error | Score on a scale | Baseline; Weeks 4, 8, 12, 16 |
|
|
|
| Secondary | Number of Participants With a Treatment-emergent Adverse Event From Day 0 to Week 8. | A participant who experienced any of the following untoward or unfavorable medical occurrence(s) associated with the investigational device or any study mandated procedures following the first stimulation on Day 0 and prior to the Week 8 visit:
| The Blinded Phase Safety population included all participants who received any active tcVNS stimulation or sham stimulation from Day 0 through the day before the Week 8 visit. | Posted | Count of Participants | Participants | Day 0 to Week 8 |
|
|
|
| Secondary | Number of Participants With a Treatment-emergent Adverse Event From Week 8 to Week 16 | A participant who experienced any of the following untoward or unfavorable medical occurrence(s) associated with the investigational device or any study mandated procedures between Week 8 and Week 16:
| The Open-Label Phase Safety population included all participants who received any active tcVNS stimulation on or after the Week 8 visit. | Posted | Count of Participants | Participants | Week 8 to Week 16 |
|
|
|
| Secondary | Number of Participants With a Treatment-emergent Serious Adverse Event From Day 0 to Week 8 | A participant who experienced any serious untoward or unfavorable medical occurrence(s) associated with the investigational device or any study mandated procedures following the first stimulation on Day 0 and prior to the Week 8 visit. | The Blinded Phase Safety population included all participants who received any active tcVNS stimulation or sham stimulation from Day 0 to the day before the Week 8 visit. | Posted | Count of Participants | Participants | Day 0 to Week 8 |
|
|
|
| Secondary | Number of Participants With a Treatment-emergent Serious Adverse Event From Week 8 to Week 16 | A participant who experienced any serious untoward or unfavorable medical occurrence(s) associated with the investigational device or any study mandated procedures between Week 8 and Week 16. | The Open-Label Phase Safety population included all participants who received any active tcVNS stimulation on or after the Week 8 visit. | Posted | Count of Participants | Participants | Week 8 to Week 16 |
|
|
|
| 0 |
| 8 |
| 0 |
| 8 |
| 3 |
| 8 |
| EG001 | Blinded Phase: Sham Stimulation | Participants stimulated themselves for 5 minutes daily with sham stimulation at the neck through the day prior to the Week 8 visit. | 0 | 9 | 0 | 9 | 0 | 9 |
| EG002 | Open-Label Phase: Active tcVNS Following Active tcVNS | Participants stimulated themselves for 5 minutes daily with active tcVNS using the investigational device at the cymba concha from Week 8 through Week 16, following active tcVNS in the 8-week blinded period. Participants are only included in the Open-Label Phase if they stimulated at least once on or after the Week 8 visit. | 0 | 7 | 0 | 7 | 2 | 7 |
| EG003 | Open-Label Phase: Active tcVNS Following Sham Stimulation | Participants stimulated themselves for 5 minutes daily with active tcVNS at the cymba concha using the investigational device from Week 8 through Week 16, following sham stimulation in the 8-week blinded period. Participants are only included in the Open-Label Phase if they stimulated at least once on or after the Week 8 visit. | 0 | 8 | 0 | 8 | 1 | 8 |
| Gastritis | Gastrointestinal disorders | 26.0 | Systematic Assessment |
|
| Medical device site irritation | General disorders | 26.0 | Systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | 26.0 | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | 26.0 | Systematic Assessment |
|
| Lymphocyte count increased | Investigations | 26.0 | Systematic Assessment |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | 26.0 | Systematic Assessment |
|
| Skin irritation | Skin and subcutaneous tissue disorders | 26.0 | Systematic Assessment |
|
Not provided
Not provided
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| Week 16 |
|
| Fisher Exact |
| 0.637 |
P-value is from comparing the proportion of JIA ACR 50 Responders between the two device groups using a Fisher's exact test. |
| Superiority |
| Week 16 | Fisher Exact | 1.00 | P-value is from comparing the proportion of JIA ACR 50 Responders between the two device groups using a Fisher's exact test. | Superiority |
| Week 12 |
|
| Week 16 |
|
| Fisher Exact |
| 1.000 |
P-value is from comparing the proportion of JIA ACR 30 Responders between the two device groups using a Fisher's exact test. |
| Superiority |
| Week 12 | Fisher Exact | 0.620 | P-value is from comparing the proportion of JIA ACR 30 Responders between the two device groups using a Fisher's exact test. | Superiority |
| Week 16 | Fisher Exact | 0.576 | P-value is from comparing the proportion of JIA ACR 30 Responders between the two device groups using a Fisher's exact test. | Superiority |
| Week 12 |
|
| Week 16 |
|
| Fisher Exact |
| 1.00 |
P-value is from comparing the proportion of JIA ACR 70 Responders between the two device groups using a Fisher's exact test. |
| Superiority |
| Week 12 | Fisher Exact | 1.000 | P-value is from comparing the proportion of JIA ACR 70 Responders between the two device groups using a Fisher's exact test. | Superiority |
| Week 16 | Fisher Exact | 0.637 | P-value is from comparing the proportion of JIA ACR 70 Responders between the two device groups using a Fisher's exact test. | Superiority |
| Week 8 |
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| ANCOVA |
| 0.500 |
P-value comes from an analysis of covariance with an outcome of change in JADAS-27 from Baseline and covariates of treatment and Baseline JADAS-27 score. |
| Superiority |
| Week 12 | ANCOVA | 0.285 | P-value comes from an analysis of covariance with an outcome of change in JADAS-27 from Baseline and covariates of treatment and Baseline JADAS-27 score. | Superiority |
| Week 16 | ANCOVA | 0.148 | P-value comes from an analysis of covariance with an outcome of change in JADAS-27 from Baseline and covariates of treatment and Baseline JADAS-27 score. | Superiority |
| Fisher Exact |
| 1.000 |
P-value is from comparing the proportion of JIA ACR 50 Responders between the two device groups using a Fisher's exact test. |
| Superiority |
| Fisher Exact |
| 1.000 |
| Superiority |
P-value is from comparing the proportion of JIA ACR 30 Responders between the two device groups using a Fisher's exact test. |
| Fisher Exact |
| 0.471 |
P-value is from comparing the proportion of JIA ACR 70 Responders between the two device groups using a Fisher's exact test. |
| Superiority |
| Week 16 |
|
|
| ANCOVA |
| 0.337 |
P-value comes from an analysis of covariance with an outcome of change in JADAS-27 from Week 8 and covariates of treatment and Week 8 JADAS-27 score. |
| Superiority |
| Week 4 |
|
|
| Week 8 |
|
|
| Week 12 |
|
|
| Week 16 |
|
|